Doctor of Osteopathy Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Kimberly Seal

Vascular Surgery Hampton, VA Doctor of Osteopathy

NPI 1912357542 CMS profile 11529168

3000 Coliseum Dr Ste 200, Hampton, VA 23666

Open in the dashboard

General payments

$3,846

81 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimberly Seal of Hampton, VA is reported in the CMS Open Payments database as having received $3,846 across 81 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 43rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,899 30
2024 General $1,002 29
2023 General $945 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberly Seal
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Kimberly Seal were reported at $1,899. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Kimberly Seal Vascular Surgery median Middle half National median
2019 $0 $796 $226–$2,363 $163
2020 $0 $348 $118–$1,110 $114
2021 $0 $471 $158–$1,421 $132
2022 $0 $725 $222–$2,183 $149
2023 $945 $836 $257–$2,440 $160
2024 $1,002 $909 $252–$2,619 $164
2025 $1,899 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Stryker Corporation $690 16 payments
  2. W. L. Gore & Associates, Inc. $658 5 payments
  3. Inari Medical, Inc. $533 29 payments
  4. Endologix, Inc. $338 4 payments
  5. Abbott Laboratories $288 2 payments
  6. Cook Medical LLC $206 3 payments
  7. Silk Road Medical, Inc. $194 3 payments
  8. Imperative Care, INc $171 1 payment
  9. Baxter Healthcare $166 4 payments
  10. Shape Memory Medical Inc. $149 1 payment
  11. Other $454 13 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $3,846 81 payments
Products named General payments · program years 2023–2025
  1. FLOWTRIEVER CATHETER, S $843 35 payments
  2. CT THROMBECTOMY SYSTEM KIT $843 35 payments
  3. ENDOCROSS Device $338 4 payments
  4. Torus Stent Graft System $338 4 payments
  5. Zenith Spiral-Z $206 3 payments
  6. ENROUTE Transcarotid Neuroprotection System $194 3 payments
  7. ENROUTE Transcarotid Stent $194 3 payments
  8. VIABAHN Endoprosthesis with PROPATEN Bioactive Surface $182 1 payment
  9. SYMPHONY CATHETER $171 1 payment
  10. SPY-PHI SYSTEM $167 1 payment
  11. Other $1,960 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

239

Median for Vascular Surgery: 122

Drug cost

$28,859

Median for Vascular Surgery: $14,135

Branded share of claims

58.2%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 23 $26,383
Clopidogrel Clopidogrel Bisulfate Brand 81 $1,013
Pentoxifylline Generic 12 $512
Atorvastatin Calcium Generic 45 $503
Cilostazol Generic 18 $205
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 20 $86
Gabapentin Generic 12 $78
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 15 $57
Tramadol Hcl Generic 13 $22

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 144 billing codes

Paid by Medicare

$119,868

Medicare's payments for the services billed

Medicare patients

587

Average age 76

Services billed

1,422

295 women, 292 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 49%
Chronic kidney disease 47%
Ischemic heart disease 45%
Heart failure 38%
COPD 29%
Atrial fibrillation 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record